BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 16216365)

  • 1. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
    Nickers P; Thissen B; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does inverse planning applied to Iridium192 high dose rate prostate brachytherapy improve the optimization of the dose afforded by the Paris system?
    Nickers P; Lenaerts E; Thissen B; Deneufbourg JM
    Radiother Oncol; 2005 Feb; 74(2):131-6. PubMed ID: 15734200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial.
    Nickers P; Coppens L; de Leval J; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jun; 79(3):329-34. PubMed ID: 16780976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma.
    Wang Y; Sankreacha R; Al-Hebshi A; Loblaw A; Morton G
    Brachytherapy; 2006; 5(4):251-5. PubMed ID: 17118319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
    Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
    D'Souza WD; Thames HD; Kuban DA
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in brachytherapy--focusing on the permanent implant for early prostate carcinoma].
    Hirokawa Y
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2056-61. PubMed ID: 14712765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
    Pickett B; Pouliot J
    Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
    Krishnamurthy D; Weinberg V; Cunha JA; Hsu IC; Pouliot J
    Brachytherapy; 2011; 10(6):461-5. PubMed ID: 21397569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.
    Yaparpalvi R; Mutyala S; Gorla GR; Butler J; Mah D; Garg MK; Kalnicki S
    Brachytherapy; 2008; 7(4):336-42. PubMed ID: 18782683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Image-guided cervix high-dose-rate brachytherapy treatment planning: does custom computed tomography planning for each insertion provide better conformal avoidance of organs at risk?
    Davidson MT; Yuen J; D'Souza DP; Batchelar DL
    Brachytherapy; 2008; 7(1):37-42. PubMed ID: 18299111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
    Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
    Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
    Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer.
    Pellizzon AC; Salvajoli JV; Maia MA; Ferrigno R; Novaes PE; Fogarolli RC; Pellizzon RJ
    J Urol; 2004 Mar; 171(3):1105-8. PubMed ID: 14767280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
    Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.